Literature DB >> 33587508

Maternal HIV Infection and Spontaneous Versus Provider-Initiated Preterm Birth in an Urban Zambian Cohort.

Joan T Price1,2,3, Bellington Vwalika2, Jessie K Edwards4, Stephen R Cole4, Margaret P Kasaro2,3, Katelyn J Rittenhouse1, Andrew Kumwenda2, Mwansa K Lubeya1, Jeffrey S A Stringer3.   

Abstract

OBJECTIVE: We investigated the effect of maternal HIV and its treatment on spontaneous and provider-initiated preterm birth (PTB) in an urban African cohort.
METHODS: The Zambian Preterm Birth Prevention Study enrolled pregnant women at their first antenatal visit in Lusaka. Participants underwent ultrasound, laboratory testing, and clinical phenotyping of delivery outcomes. Key exposures were maternal HIV serostatus and timing of antiretroviral therapy initiation. We defined the primary outcome, PTB, as delivery between 16 and 37 weeks' gestational age, and differentiated spontaneous from provider-initiated parturition.
RESULTS: Of 1450 pregnant women enrolled, 350 (24%) had HIV. About 1216 (84%) were retained at delivery, 3 of whom delivered <16 weeks. Of 181 (15%) preterm deliveries, 120 (66%) were spontaneous, 56 (31%) were provider-initiated, and 5 (3%) were unclassified. In standardized analyses using inverse probability weighting, maternal HIV increased the risk of spontaneous PTB [RR 1.68; 95% confidence interval (CI): 1.12 to 2.52], but this effect was mitigated on overall PTB [risk ratio (RR) 1.31; 95% CI: 0.92 to 1.86] owing to a protective effect against provider-initiated PTB. HIV reduced the risk of preeclampsia (RR 0.32; 95% CI: 0.11 to 0.91), which strongly predicted provider-initiated PTB (RR 17.92; 95% CI: 8.13 to 39.53). The timing of antiretroviral therapy start did not affect the relationship between HIV and PTB.
CONCLUSION: The risk of HIV on spontaneous PTB seems to be opposed by a protective effect of HIV on provider-initiated PTB. These findings support an inflammatory mechanism underlying HIV-related PTB and suggest that published estimates of PTB risk overall underestimate the risk of spontaneous PTB.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33587508      PMCID: PMC8131221          DOI: 10.1097/QAI.0000000000002654

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  61 in total

1.  Preeclampsia and HIV infection.

Authors:  Rosiane Mattar; Abes M Amed; Prescilla C Lindsey; Nelson Sass; Silvia Daher
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-12-01       Impact factor: 2.435

Review 2.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

3.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

Review 4.  The enigma of spontaneous preterm birth.

Authors:  Louis J Muglia; Michael Katz
Journal:  N Engl J Med       Date:  2010-02-11       Impact factor: 91.245

5.  Associations between HIV, highly active anti-retroviral therapy, and hypertensive disorders of pregnancy among maternal deaths in South Africa 2011-2013.

Authors:  Hannah M Sebitloane; Jagidesa Moodley; Benn Sartorius
Journal:  Int J Gynaecol Obstet       Date:  2016-11-22       Impact factor: 3.561

6.  Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.

Authors:  Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Chipo Petlo; Shahin Lockman; Joseph Makhema; Roger L Shapiro
Journal:  JAMA Pediatr       Date:  2017-10-02       Impact factor: 16.193

7.  Timing of Initiation of Antiretroviral Therapy and Risk of Preterm Birth in Studies of HIV-infected Pregnant Women: The Role of Selection Bias.

Authors:  Marie C D Stoner; Stephen R Cole; Joan Price; Jennifer Winston; Jeffrey S A Stringer
Journal:  Epidemiology       Date:  2018-03       Impact factor: 4.822

Review 8.  Medically indicated preterm birth: recognizing the importance of the problem.

Authors:  Cande V Ananth; Anthony M Vintzileos
Journal:  Clin Perinatol       Date:  2008-03       Impact factor: 3.430

9.  Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.

Authors:  Catherine A Koss; Paul Natureeba; Albert Plenty; Flavia Luwedde; Julia Mwesigwa; Veronica Ades; Edwin D Charlebois; Tamara D Clark; Jane Achan; Theodore Ruel; Bridget Nzarubara; Moses R Kamya; Diane V Havlir; Deborah Cohan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-10-01       Impact factor: 3.731

10.  Pro-Inflammatory Cytokine Levels in HIV Infected and Uninfected Pregnant Women with and without Preeclampsia.

Authors:  Niren Ray Maharaj; Alisa Phulukdaree; Savania Nagiah; Prithiksha Ramkaran; Charlette Tiloke; Anil Amichund Chuturgoon
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

View more
  2 in total

1.  HIV-associated vaginal microbiome and inflammation predict spontaneous preterm birth in Zambia.

Authors:  Joan T Price; Bellington Vwalika; Michael France; Jacques Ravel; Bing Ma; Humphrey Mwape; Katelyn J Rittenhouse; Kristina De Paris; Marcia Hobbs; Julie A Nelson; Margaret P Kasaro; Elizabeth M Stringer; Jeffrey S A Stringer
Journal:  Sci Rep       Date:  2022-05-20       Impact factor: 4.996

2.  Risk of Adverse Birth Outcomes in Two Cohorts of Pregnant Women With HIV in Zambia.

Authors:  Joan T Price; Yuri V Sebastião; Bellington Vwalika; Stephen R Cole; Felistas M Mbewe; Winifreda M Phiri; Bethany L Freeman; Margaret P Kasaro; Marc Peterson; Dwight J Rouse; Elizabeth M Stringer; Jeffrey S A Stringer
Journal:  Epidemiology       Date:  2022-05-01       Impact factor: 4.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.